- Home
- ACXP
as 12-18-2024 10:30am EST
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration.
| Founded: | 2017 | Country: | United States |
| Employees: | N/A | City: | STATEN ISLAND |
| Market Cap: | 31.4M | IPO Year: | 2021 |
| Target Price: | $12.00 | AVG Volume (30 days): | 297.3K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.07 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.72 - $5.28 | Next Earning Date: | 11-12-2024 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Acurx Pharmaceuticals Inc. News
ACXP Breaking Stock News: Dive into ACXP Ticker-Specific Updates for Smart Investing
ACCESSWIRE
7 days ago
Acurx Pharmaceuticals to Present at the Microcap Conference, January 28, 2025 - January 30, 2025
PR Newswire
9 days ago
Acurx Updates Phase 3 Readiness for Ibezapolstat in C. difficile Infection Based on Recent FDA and EMA Communications
Zacks
20 days ago
Here's Why Acurx Pharmaceuticals (ACXP) Is a Great 'Buy the Bottom' Stock Now
ACCESSWIRE
21 days ago
DealFlow Events Unveils First Wave of Companies for The Microcap Conference in January 2025
Barrons.com
a month ago
MicroStrategy Copycats Are Buying Bitcoin as Price Nears $100,000
PR Newswire
a month ago
Acurx Board of Directors Approves Bitcoin as Treasury Reserve Asset
PR Newswire
a month ago
Acurx Sponsored and Participated in the Peggy Lillis Foundation Inaugural CDI Scientific Symposium and Presented Ibezapolstat Ph2b Clinical Data Update
GuruFocus.com
a month ago
Acurx Pharmaceuticals Inc (ACXP) Q3 2024 Earnings Call Highlights: Strategic Advances Amid ...
Compare ACXP vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ACXP Acurx Pharmaceuticals Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.